Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat solid tumors while preserving organ function. Its lead candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate (VDC) in late-stage clinical development for early choroidal melanoma, as well as metastases to the choroid, cancers of the ocular surface, and non-muscle invasive bladder cancer (NMIBC). Bel-sar uses modified HPV capsid proteins conjugated to light-activated molecules to selectively kill tumor cells.
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-130401 | EDGAR | 93K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043943 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-036814 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0000950170-23-008166 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0000950170-22-004425 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-278817 | EDGAR | 60K words |
| 2025-08-13 | 2025-06-30 | 0001193125-25-179426 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071907 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125428 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093308 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056265 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062097 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040138 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021302 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024150 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016911 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009719 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-130383 | EDGAR | 3K words |
| 2025-11-13 | 0001193125-25-278810 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179418 | EDGAR | — |
| 2025-06-18 | 0000950170-25-087885 | EDGAR | — |
| 2025-05-16 | 0001193125-25-121677 | EDGAR | — |
| 2025-05-15 | 0000950170-25-071839 | EDGAR | — |
| 2025-04-02 | 0000950170-25-048880 | EDGAR | — |
| 2025-03-24 | 0000950170-25-043809 | EDGAR | — |
| 2024-11-12 | 0000950170-24-125390 | EDGAR | — |
| 2024-10-17 | 0001193125-24-238959 | EDGAR | — |
77 total filings indexed. 50 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501796 |
| Ticker | AURA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.aurabiosciences.com |
| Listed | 2021-10-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report